Skip to main
ALKS

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 43%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Alkermes PLC is positioned for revenue growth through 2030, bolstered by the acquisition of Lumryz, which is anticipated to contribute approximately $265-$275 million in annualized sales by 2025, with further growth expected in the subsequent years, particularly in the narcolepsy and idiopathic hypersomnia markets. The company's ongoing investments in its innovative product pipeline, including alixorexton, are expected to enhance earnings per share while supporting essential Phase III development programs. Overall, the acquisition of Lumryz presents a strategic opportunity that strengthens Alkermes's commercial operations and reinforces its financial outlook without excessively burdening its balance sheet.

Bears say

Alkermes PLC faces a negative outlook primarily due to potential sales declines and competitive pressures affecting its key product, Lumryz, which is projected to peak at approximately $600 million by 2030 before experiencing annual declines coinciding with patent expirations and increased competition from other OX2R agonists. Additionally, significant risks surround the company's reliance on its royalty business and early-stage orexin data, which requires further validation, while potential erosion of market share for oxybates could hinder overall growth in the narcolepsy market. Finally, a downward adjustment in the EBITDA multiple reflects a more cautious assessment of the company's future cash flows, indicating concerns over the sustainability of its growth trajectory in light of emerging competition and existing market dynamics.

Alkermes (ALKS) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 43% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 14 analysts, Alkermes (ALKS) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.